Acurx announces new microbiome data from its phase 2a clinical trial of ibezapolstat for cdi in a scientific poster presentation at idweek 2021 conference

Staten island, n.y., sept. 27, 2021 /prnewswire/ -- acurx pharmaceuticals, inc. (nasdaq: acxp) ("acurx" or the "company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a scientific abstract and poster presentation will be given at the infectious disease society of america (idsa) idweektm  2021, taking place virtually from september 29 – october 3, 2021: title: an open-label phase 2a study of ibezapolstat, a unique gram-positive selective spectrum (gpss™) antibiotic, for patients with clostridioides difficile infection presenting author: professor kevin garey, pharmd, ms, university of houston date:  wednesday, september 29, 2021 through sunday, october 3, 2021 poster session: enteric infections poster number: 701 about clostridioides difficile infection (cdi).
ACXP Ratings Summary
ACXP Quant Ranking